PF-06473871 + PF-06473871
Phase 2Terminated 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hypertrophic Scars Resulting From Prior Breast Scar Revision Surgery
Conditions
Hypertrophic Scars Resulting From Prior Breast Scar Revision Surgery
Trial Timeline
Dec 1, 2014 → Jan 1, 2015
NCT ID
NCT02205476About PF-06473871 + PF-06473871
PF-06473871 + PF-06473871 is a phase 2 stage product being developed by Pfizer for Hypertrophic Scars Resulting From Prior Breast Scar Revision Surgery. The current trial status is terminated. This product is registered under clinical trial identifier NCT02205476. Target conditions include Hypertrophic Scars Resulting From Prior Breast Scar Revision Surgery.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02205476 | Phase 2 | Terminated |
| NCT01730339 | Phase 2 | Completed |
Competing Products
20 competing products in Hypertrophic Scars Resulting From Prior Breast Scar Revision Surgery
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Mavacamten | LianBio | Phase 1 | 25 |
| Mavacamten + Placebo | LianBio | Phase 3 | 69 |
| CT-G20 + Placebo | Celltrion | Phase 1 | 33 |
| candesartan | AstraZeneca | Phase 2 | 52 |
| LCZ696 + Placebo | Novartis | Phase 2 | 52 |
| Eleclazine + Placebo | Gilead Sciences | Phase 2/3 | 64 |
| Ranolazine | Gilead Sciences | Approved | 84 |
| PF-06473871 + PF-06473871 | Pfizer | Phase 2 | 51 |
| EXC 001 + EXC 001 + EXC 001 + EXC 001 | Pfizer | Phase 2 | 51 |
| Mavacamten | Bristol Myers Squibb | Approved | 84 |
| Mavacamten + Placebo | Bristol Myers Squibb | Phase 3 | 76 |
| Mavacamten | Bristol Myers Squibb | Pre-clinical | 22 |
| Mavacamten | Bristol Myers Squibb | Pre-clinical | 22 |
| Mavacamten | Bristol Myers Squibb | Approved | 84 |
| MYK-224 | Bristol Myers Squibb | Phase 2 | 51 |
| mavacamten | Bristol Myers Squibb | Phase 2/3 | 64 |
| mavacamten | Bristol Myers Squibb | Phase 2 | 51 |
| Mavacamten | Bristol Myers Squibb | Pre-clinical | 22 |
| Mavacamten | Bristol Myers Squibb | Pre-clinical | 22 |
| Mavacamten + Placebo | Bristol Myers Squibb | Phase 3 | 76 |